article thumbnail

ACE Inhibitor Not Protective Against Heart Damage from Chemotherapy

DAIC

The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines. The mean dose of enalapril among those who were randomized to take the ACE inhibitor was 17.7mg.

article thumbnail

Risk of Initiating ACE Inhibitors/ARBs in Advanced CKD

American College of Cardiology

Can patients with advanced chronic kidney disease (CKD) be initiated on angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARBs) without increasing their risk for needing kidney failure replacement therapy?

article thumbnail

PROACT: Do ACE Inhibitors Help Prevent Cardiotoxicity in Patients Treated For Breast Cancer or Lymphoma?

American College of Cardiology

24 in Atlanta.

article thumbnail

Should ACE Inhibitors and ARBs Be Continued Perioperatively?

NEJM Journal Watch - Cardiology

NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary

article thumbnail

Rates of Sudden Death After Myocardial Infarction—VALIANT and PARADISE-MI Trials

JAMA Cardiology

This secondary analysis of the Valsartan in Acute Myocardial Infarction (VALIANT) and Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) randomized clinical trials investigates the changes over time in sudden death rate after myocardial infarction and the characteristics of people (..)

article thumbnail

Prospective ARNI versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI

American College of Cardiology

The goal of the PARADISE-MI trial was to assess the efficacy and safety of sacubitril/valsartan compared with ramipril in a contemporary acute myocardial infarction (AMI) population.

article thumbnail

ACE Inhibitor and Angiotensin Receptor Blocker use during Pregnancy: data from the ESC Registry Of Pregnancy And Cardiac disease (ROPAC)

The American Journal of Cardiology

Publication date: Available online 7 August 2024 Source: The American Journal of Cardiology Author(s): Johanna A. van der Zande, Karishma P. Ramlakhan, Katja Prokselj, Edison Muñoz-Ortiz, Amalia Baroutidou, Magdalena Lipczynska, Edit Nagy, Tobias Rutz, Arie Franx, Roger Hall, Mark R. Johnson, Jolien W. Roos-Hesselink, ROPAC investigators